Ameriflex Group Inc. Purchases Shares of 1,712 Moderna, Inc. (NASDAQ:MRNA)

Ameriflex Group Inc. purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, Holdings Channel reports. The fund purchased 1,712 shares of the company’s stock, valued at approximately $67,000.

Several other institutional investors and hedge funds also recently modified their holdings of MRNA. Norges Bank purchased a new stake in shares of Moderna in the fourth quarter valued at about $163,833,000. Voloridge Investment Management LLC lifted its holdings in shares of Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after purchasing an additional 1,996,003 shares in the last quarter. FMR LLC lifted its holdings in shares of Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock valued at $776,075,000 after purchasing an additional 1,282,469 shares in the last quarter. Pictet Asset Management Holding SA lifted its holdings in shares of Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock valued at $73,447,000 after purchasing an additional 1,113,455 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Moderna by 24.3% in the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock valued at $208,169,000 after purchasing an additional 979,858 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. cut their price objective on shares of Moderna from $33.00 to $26.00 and set an “underweight” rating for the company in a research report on Thursday, May 22nd. Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective for the company. UBS Group cut their price objective on shares of Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Barclays cut their price objective on shares of Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a research report on Friday, May 2nd. Finally, Morgan Stanley cut their price objective on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $53.58.

Moderna Trading Up 1.9%

Shares of NASDAQ MRNA opened at $26.76 on Wednesday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $164.73. The company has a market cap of $10.35 billion, a P/E ratio of -2.88 and a beta of 1.99. The stock has a fifty day moving average price of $26.83 and a 200 day moving average price of $34.20.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business’s quarterly revenue was down 35.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($3.07) earnings per share. On average, sell-side analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.